| Identification | Back Directory | [Name]
GTCpFE | [CAS]
1588866-45-8 | [Synonyms]
GTCpFE
2-Butenedioic acid (2E)-, 1-[[4-[[2-(acetyloxy)benzoyl]oxy]phenyl]methyl] 4-ethyl ester | [Molecular Formula]
C22H20O8 | [MOL File]
1588866-45-8.mol | [Molecular Weight]
412.39 |
| Hazard Information | Back Directory | [Uses]
GTCpFE inhibits IKKα/β in the NF-κB pathway with anti-inflammatory activities and blocks p65 nuclear entry, which consists of Dimethyl fumarate (DMF) (HY-17363) linked to Aspirin (ASA) (HY-14654). GTCpFE exhibits selective anti-cancer stem-like cell (CSC) activity by reducing mammosphere growth and the CD44+ CD24- immunophenotype. GTCpFE inhibits breast cancer stem cells, an important NFκB- and PGE2-dependent phenotype in aggressive cancers[1][2]. | [References]
[1] Kastrati I, et al. Design and synthesis of hybrid drugs to target inflammatory pathways in breast cancer[J]. Cancer Research, 2015, 75(15_Supplement): 4497-4497.
[2] Kastrati I, et al. A novel aspirin prodrug inhibits NFκB activity and breast cancer stem cell properties. BMC Cancer. 2015 Nov 4;15:845. DOI:10.1186/s12885-015-1868-7 |
|
|